Orphan Drugs
-
Caught my eye, Generics, Healthcare Costs, ICER, Inflation Reduction Act, Medicaid, Medicare Negotiation, Medicare Part D, Orphan Drugs, State-based Reform, ValueCaught my eye — 03/07/25
Read more: Caught my eye — 03/07/25Tuesday morning, I spent the first half of the day convinced it was Wednesday, and yet, despite that mental setback, the rest of the week has flown by. Feels like a win. Killing me softly. Overall, glad to see the stories recognizing how the uncertainty of federal research dollars is impacting NIH summer internships, graduate…
-
On the Horizon — Orphan Drugs and IRA
Read more: On the Horizon — Orphan Drugs and IRANot everything can be important, or nothing is. It’s the time of year when white boards and Post-It easels come out and prioritization for 2025 gets reviewed. From a consultant perspective, I love these exercises. It allows for a look at what needs direct action, coalition or monitoring. And the $ has to go to…
-
Orphan drug: Expand the label and you lose
Read more: Orphan drug: Expand the label and you loseFrom a patient perspective, the Inflation Reduction Act (IRA) definitely has some upside. Starting in 2024, the out-of-pocket cap in the Medicare prescription drug benefit starting is fantastic for beneficiaries taking more expensive products. Although this is a minority of patients, it still gives piece of mind to many knowing that if they find themselves…
Latest news
- Caught my eye — 03/28/25
- Caught my eye — 3/21/25
- Caught my eye — 3/14/25
- Caught my eye — 03/07/25
- Caught my eye — 2/28/25
Categories
- 340B (33)
- Affordable Care Act (4)
- Alzheimer's (5)
- Biosimilars (20)
- Caught my eye (61)
- Cell and Gene (1)
- Chevron Deference (2)
- CMMI (10)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (30)
- Drug shortages (8)
- DTC (2)
- Employers (7)
- Generics (5)
- Health Equity (3)
- Healthcare Costs (28)
- ICER (9)
- Importation (2)
- Inflation Reduction Act (45)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (6)
- Medicare Advantage (15)
- Medicare Negotiation (48)
- Medicare Part D (44)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (7)
- Obesity (20)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (28)
- Reference Pricing (5)
- State-based Reform (14)
- Supply Chain (1)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (4)
- Value (12)